Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 180 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: insulin aspart Clear all
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Not applicable Interventional Results available

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

NCT00574405
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
Drug · Device
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
8 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 4 Interventional Results available

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01848990
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Concord, California • Encino, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Mylan Insulin Aspart Study

NCT03760068
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
MYL-1601D Product, FlexPen NovoLog®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
158
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Insulins Aspart and Lispro in Insulin Pumps

NCT00461331
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart, Insulin Lispro
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01513473
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

NCT00972283
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
66
States / cities
Alexander City, Alabama • Birmingham, Alabama • Goodyear, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 4 Interventional Results available

Linagliptin Inpatient Trial

NCT02004366
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Not applicable Interventional Results available

Mechanisms of Insulin Facilitation of Memory

NCT01145482
View directory record Official record
Conditions
Memory Disorders
Interventions
Insulin, Saline
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 1 Interventional

Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy

NCT03234491
View directory record Official record
Conditions
Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia
Interventions
DiAS, Afrezza low dose, Afrezza high dose
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA

NCT00920725
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Insulin (Aspart Insulin [Novolog], Regular Insulin)
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

NCT02825251
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Encino, California • Fresno, California • Roseville, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 4, 2026, 6:07 PM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 4, 2026, 6:07 PM EDT
Terminated Not applicable Interventional

Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart

NCT00206206
View directory record Official record
Conditions
Hyperglycemia
Interventions
Hyperglycemia Protocol Procedure
Procedure
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2006 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

NCT03211858
View directory record Official record
Conditions
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions
Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

NCT02443402
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

NCT00313001
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 1 Interventional

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

NCT01464099
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 4 Interventional

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Aspart
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 4, 2026, 6:07 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

NCT06547619
View directory record Official record
Conditions
Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity
Interventions
Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

NCT03268005
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
64
States / cities
Concord, California • Fresno, California • Fullerton, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 4, 2026, 6:07 PM EDT
Terminated Phase 4 Interventional Results available

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

NCT03511521
View directory record Official record
Conditions
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions
NPH Insulin, glargine, Insulin Aspart
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

NCT01831765
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
116
States / cities
Mobile, Alabama • Tucson, Arizona • Anaheim, California + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

NCT00065130
View directory record Official record
Conditions
Diabetes, Gestational Diabetes
Interventions
human insulin, insulin NPH, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 4, 2026, 6:07 PM EDT